• Je něco špatně v tomto záznamu ?

Úprava koagulopatie při krvácení do mozku v souvislosti s warfarinem
[Correction of coagulopathy in warfarin associated cerebral hemorrhage]

Venkatesh Aiyagari, Fernando D. Testai

Jazyk čeština Země Česko

Typ dokumentu přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc07526443

Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.

Correction of coagulopathy in warfarin associated cerebral hemorrhage

Bibliografie atd.

Lit.: 45

000      
00000naa 2200000 a 4500
001      
bmc07526443
003      
CZ-PrNML
005      
20111210143031.0
008      
090724s2009 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Aiyagari, Venkatesh $7 gn_A_00002755
245    10
$a Úprava koagulopatie při krvácení do mozku v souvislosti s warfarinem / $c Venkatesh Aiyagari, Fernando D. Testai
246    11
$a Correction of coagulopathy in warfarin associated cerebral hemorrhage
314    __
$a Department of Neurology and Rehabilitation, University of Illinois at Chicago, Chicago aiyagari@uic.edu
504    __
$a Lit.: 45
520    9_
$a Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.
650    _2
$a koagulopatie $x farmakoterapie $7 D001778
650    _2
$a warfarin $x farmakologie $x krev $x škodlivé účinky $7 D014859
650    _2
$a aplikace orální $7 D000284
650    _2
$a intrakraniální krvácení $7 D020300
650    _2
$a antikoagulancia $x farmakologie $x krev $x škodlivé účinky $7 D000925
650    _2
$a vitamin K $x aplikace a dávkování $x terapeutické užití $7 D014812
650    _2
$a nenasazení léčby $7 D028761
650    _2
$a farmakoterapie $x metody $7 D004358
650    _2
$a krevní plazma $7 D010949
650    _2
$a protrombin $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D011516
650    _2
$a faktor VII $x aplikace a dávkování $x terapeutické užití $7 D005167
650    _2
$a INR $7 D019934
650    _2
$a hemokoagulace $7 D001777
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a lidé $7 D006801
655    _2
$a přehledy $7 D016454
700    1_
$a Testai, Fernando D.
773    0_
$w MED00156011 $t Current opinion in critical care $g Roč. 3, č. 2 (2009), s. 25-30 $x 1802-3819
910    __
$a ABA008 $b B 2484 $c 422 $y 9
990    __
$a 20090724112807 $b ABA008
991    __
$a 20090811092001 $b ABA008
999    __
$a ok $b bmc $g 668817 $s 526077
BAS    __
$a 3
BMC    __
$a 2009 $b 3 $c 2 $d 25-30 $i 1802-3819 $m Current Opinion in Critical Care (České vyd.) $x MED00156011
LZP    __
$a 2009-25/mkrk

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...